You are here

Company Monitoring Page for Novartis

latest headlines for company on cafepharma

FDA approves ex-Novartis drug for Cushing’s disease

Endpoints

Mon, 03/9/20 - 10:17 am

Tags:

FDA, Cushing's disease, Isturisa, Novartis, Recordati

Novartis taps Orionis to pursue 'historically elusive targets'

Fierce Biotech

Thu, 03/5/20 - 10:55 am

Tags:

Novartis, Orionis Biosciences, drug discovery

'Lightning struck': How a safety alert shifted doctor sentiment on Novartis' Beovu

Fierce Pharma

Wed, 03/4/20 - 10:57 am

Tags:

Novartis, Beovu, ASRS, occlusive vasculitis, wet age-related macular degeneration, physicians

With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug

Endpoints

Tue, 03/3/20 - 11:02 am

Tags:

Pliant Therapeutics, IPF, Biogen, Novartis

Sandoz Pays $195 Million to Settle Criminal Antitrust Charges in Sweeping Federal Probe

BioSpace

Tue, 03/3/20 - 10:55 am

Tags:

Sandoz, generics, Novartis, antitrust

Morphosys’ off-the-shelf rival to CAR-T approaches finish line with a speedy review

Endpoints

Mon, 03/2/20 - 09:37 am

Tags:

MorphoSys, Gilead Sciences, Novartis, CAR-T, tafasitamab, DLBCL

Novartis knocked by safety scare

EP Vantage

Tue, 02/25/20 - 04:55 pm

Tags:

Novartis, Regeneron, Beovu, Eylea, wet age-related macular degeneration

Novartis' hot new eye drug Beovu tied to potential vision loss: experts

Fierce Pharma

Tue, 02/25/20 - 10:02 am

Tags:

Novartis, Beovu, retinal vasculitis, wet age-related macular degeneration

Novartis gets a boost in blockbuster multiple sclerosis race with Roche

Endpoints

Mon, 02/24/20 - 10:41 am

Tags:

Novartis, MS, multiple sclerosis, FDA, priority reviews, Arzerra

With supply tight, Novartis readies gene therapy plant for production

BioPharma Dive

Fri, 02/21/20 - 11:45 pm

Tags:

Novartis, Zolgensma, spinal muscular atrophy, drug manufacturing

New Meds Set to Reshape US CNS and oncology Markets

Xconomy

Tue, 02/18/20 - 08:36 pm

Tags:

CNS, oncology, cancer, Clarivate Analytics, Biohaven, rimegepant, Novartis, OMB-157

Former Novartis exec pleads guilty to generic price fixing

Endpoints

Tue, 02/18/20 - 10:25 am

Tags:

Novartis, Sandoz, price fixing, generics, DOJ

Blockbusters in waiting: drug launches to watch in 2020

Pharmaforum

Mon, 02/17/20 - 11:33 pm

Novartis plots cardio trial in UK as London HQ opens

Pharmaforum

Wed, 02/12/20 - 10:52 am

Tags:

Novartis, clinical trials, London, UK, inclisiran

Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs

Endpoints

Tue, 02/11/20 - 10:28 am

Tags:

Incyte, Novartis, FDA, capmatinib, prioirty review, non-small cell lung cancer

Multiple Sclerosis Update: Biogen, Sanofi, Active, Adamas and Novartis

BioSpace

Sun, 02/9/20 - 04:01 pm

Tags:

MS, multiple sclerosis, Biogen, Sanofi, Active Biotech, Mylan, Novartis, Adamas

Are Novartis and Regeneron seeing the same thing?

BioPharma Dive

Fri, 02/7/20 - 11:42 pm

Tags:

Novartis, Regeneron, physicians, Eylea, Beovu

Novartis faces criticism over Zolgensma ‘health lottery’

PM Live

Thu, 02/6/20 - 11:51 pm

Tags:

Novartis, SMA, gene therapy, Zolgensma, lottery

Sandoz Completes Acquisition of Aspen's Japanese Operations

BioSpace

Sat, 02/1/20 - 11:49 pm

Tags:

Sandoz, Aspen Global, Japan, M&A, Novartis

Novartis' Sandoz loses bid to break United Therapeutics' exclusive device deal for Remodulin

Fierce Pharma

Thu, 01/30/20 - 09:17 pm

Tags:

Novartis, Sandoz, United Therapeutics, Remodulin

Pages

last 30 twitter posts